The study result of the effect of Jirug-6 suppositories on vaginal candidiasis model in experimental animals

Abstract

Background: Vaginal candidiasis is a highly prevalent infectious disease among women caused by a wide range of pathogenic organisms. Although it can be treated with standard pharmacological methods, it has detrimental effects on women’s reproductive health. The absence of research to date on the anti-vaginal inflammatory effects of Jirug-6 suppositories - a traditional formulation derived from ancient medicinal recipes and long-used in traditional mongolian medicine has provided the rationale for conducting this study. Aim: Study of the effects of Jirug-6 suppositories on the vaginal inflammatory lesion model induced by Candida albicans. Materials and Methods: To establish the vaginal inflammatory lesion model in experimental animals, the inoculum was prepared according to the McFarland standard method, and 10 µL of the inoculum was intravaginally administered daily for 4 consecutive days. Fifty-six mice with induced vaginal candidiasis were divided into 7 groups. On treatment days 1, 3, 5, 7, and 10, the vaginal cavity of the mice was washed with 100 µL of phosphate buffer. From the lavage fluid, 20 µL was collected, mixed with 480 µL of phosphate buffer, and thoroughly homogenized. Using a 20 µL micropipette, three aliquots were inoculated onto Sabouraud Dextrose Agar (SDA) medium and incubated at 37°C for 48 hours. Colonies were counted, and at the end of the experiment, serum was isolated from blood samples, and IFN-γ and IL-10 levels in the samples were quantified using ELISA. Histopathological analysis was performed on vaginal tissues from the experimental animals. Results: In the experimental animals, Jirug-6 suppositories 0.4 mg/kg dose exhibited the mildest clinical signs of hyperemia, swelling, hemorrhage, infiltration, or fluid loss into soft tissues in the vaginal and cervical regions (p<0.01). For cervical inflammation, Jirug-6 suppositories 0.4 mg/kg demonstrated a strong anti-inflammatory effect with a score of 1.99±0.78, which was comparable to the positive control group (p<0.01). In serum, the concentrations of IFN-γ and IL-10 in Jirug-6 suppositories 0.4 mg/kg were determined to be 8.18±0.61 and 7.91±1.30, respectively, showing reduced levels similar to those of the positive control group (p<0.01). Conclusions: 1. Jirug-6 suppositories reduce inflammatory symptoms and suppresses fungal dissemination during the vaginal lesion model induced by C. albicans. 2. At a Jirug-6 suppositories 0.4 mg/kg demonstrates anti-inflammatory effects by increasing IFN-γ concentration and decreasing IL-10 concentration in the C. albicans-induced vaginal lesion model. Furthermore, it enhances immunity and reduces swelling during inflammation, exhibiting positive therapeutic effects against clinical symptoms.